By DrBicuspid Staff

April 2, 2015 -- A new survey by Vigilant Biosciences has found that most U.S. consumers know little or nothing about oral cancer. This offers a clear opportunity for dentists to educate their patients on the disease, the company noted.

Vigilant polled more than 1,000 consumers ages 35 to 75 on their knowledge of oral cancer and oral cancer screening from March 16-23, 2015. More than two-thirds (68%) said they knew little or nothing at all about the disease. Additionally, only about one-third (37%) of respondents reported being screened for oral cancer at their last dental visit, but about 81% of them wanted to be screened for oral cancer at every dental checkup.

Click image to enlarge.

Oral cancer infographic. Image courtesy of Vigilant Biosciences.

Oral cancer infographic. Image courtesy of Vigilant Biosciences.

"This survey's findings demonstrate the need for greater awareness and education around this deadly disease, as well as the desire for increased screening," stated Matthew H.J. Kim, founder and CEO of Vigilant, in a press release. "Hundreds of thousands continue to be diagnosed with late-stage oral cancer every year, but we can reduce those numbers ... through early detection and a commitment to engage in conversations about risk factors."

Other findings from the survey include the following:

  • Only about a quarter (24%) recall talking to their dentist about oral cancer risks at their last checkup.
  • About a third (34%) did not know that exposure to human papillomavirus (HPV) is a risk factor for oral cancer.
  • Only 16% knew that 40% of people with oral cancer die within five years of diagnosis.

"Regular screening and early detection are absolutely essential in the fight against oral cancer," John Comisi, DDS, Vigilant's chief dental officer, said in the release. "Any steps we can take to raise awareness about this issue and enhance screening practices will help us increase the survival rate for oral cancer."

Developer of oral cancer testing system motivated by parents' disease
They say necessity is the mother of invention. But for Matthew H.J. Kim, founder and CEO of Vigilant Biosciences, the motivation for developing the OncAlert...
Vigilant debuts OncAlert system at IDS, signs distribution deals
Vigilant Biosciences is debuting its OncAlert oral cancer risk assessment system at this week's International Dental Show (IDS) in Cologne, Germany.
Vigilant raises $5.5M in funding
Vigilant Biosciences has raised $5.5 million in Series B funding. The company intends to use the newly raised funds to get U.S. and European approval...
Vigiliant marks milestone certification
Vigilant Biosciences has received International Organization for Standardization (ISO) 13485:2003 certification, an internationally recognized quality...
New 'rinse and spit' oral cancer test shows promise
A "rinse and spit" test for early detection of oral cancer performed well in a clinical feasibility study, according to Vigilant Biosciences, the company...

Copyright © 2015

Last Updated hh 4/1/2015 9:41:44 PM